Better Molecular Diagnostics for less frequent diseases
Diagnovus is a molecular diagnostic company developing assays for less frequent diseases. Our goal is to provide a differentiated, specialized and integrated assessment of a patient’s risk for disease progression, disease recurrence and prognosis as well as therapeutic prediction, aiding physicians and health care professionals in making vital decisions concerning the treatment of these diseases. With more precise information, doctors will be able to choose or modify the appropriate therapeutic regimens, leading to better outcomes for their patients.
Genomic Testing to help clinicians treat patients better
ENGAUGE™-cancer-DLBCL is the first commercially available genomic test to help clinicians treating patients with diffuse large b-cell lymphoma (DLBCL) determine their risk classification through the assessment of lymphoid tissue. DLBCL is characterized by a markedly heterogeneous clinical course. ENGAUGE™-cancer-DLBCL combines a patient’s clinical variables with the expression of cancer-related genes to capture such heterogeneity allowing for more accurate stratification guiding risk-adjusted therapies.
Recent Diagnovus News
- Dec4First Comprehensive DLBCL Gene Panel launched by Diagnovus
- Nov12Diagnovus is in the Final Group presentation at Southeastern...
- Oct15Diagnovus' interview with Genome Web